From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Short-Course TB Prophylaxis in HIV-Infected Persons.

Tuberculosis (TB) prophylaxis is recommended for all patients with HIV infection and latent TB infection, because of the high risk of developing active TB. But 12-month isoniazid (INH)-containing regimens pose difficulties with adherence and toxicity. This cost-effectiveness analysis, based on data from six clinical trials, compared the standard 12-month regimen (daily INH) with several short-course regimens in hypothetical HIV-infected patients with CD4 cell counts of 200/mm3 or less and positive tuberculin skin tests.

Short-course regimens included INH daily or twice weekly for 6 months; INH and rifampin (RIF) daily for 3 months; INH, RIF, and pyrazinamide (PZA) daily for 3 months; and RIF and PZA daily or twice a week for 2 months. Compared with no prophylaxis, all regimens improved life expectancy (by 0.42 to 0.73 years), lifetime active-TB incidence (6 to 10 fewer cases per 100), and quality-adjusted life expectancy. All standard and short-course regimens yielded savings in direct medical care costs except for the daily INH/RIF/PZA regimen; it cost $1,941 to increase life expectancy by 1 quality-adjusted life year, it was the least effective, and it was associated with the most side effects. Of all the short-course regimens, 2 months of daily RIF/PZA produced cost savings and benefits most similar to the standard 12-month regimen.

Comment: TB prophylaxis is clearly indicated for patients with HIV infection. This study suggests that short-course regimens are reasonable options. The impact of highly active antiretroviral therapy on these treatment decisions remains to be seen.

— R Saitz

Published in Journal Watch General Medicine December 8, 1998

Citation(s):

Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons: A decision and cost-effectiveness analysis. Ann Intern Med 1998 Nov 15 129 779-786.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 1998. Massachusetts Medical Society. All rights reserved.